NO20042925L - Saltformer av E-2-metoksy-N-(3-(4-(3-metyl-pyridin-3-yloksy)-fenylamino)-kinazolin-6-yl)-allyl)acetamid, samt fremstilling og anvendelse derav mot cancer - Google Patents

Saltformer av E-2-metoksy-N-(3-(4-(3-metyl-pyridin-3-yloksy)-fenylamino)-kinazolin-6-yl)-allyl)acetamid, samt fremstilling og anvendelse derav mot cancer

Info

Publication number
NO20042925L
NO20042925L NO20042925A NO20042925A NO20042925L NO 20042925 L NO20042925 L NO 20042925L NO 20042925 A NO20042925 A NO 20042925A NO 20042925 A NO20042925 A NO 20042925A NO 20042925 L NO20042925 L NO 20042925L
Authority
NO
Norway
Prior art keywords
quinazolin
phenylamino
yloxy
pyridin
acetamide
Prior art date
Application number
NO20042925A
Other languages
English (en)
Inventor
John Charles Kath
Daniel Tyler Richter
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20042925L publication Critical patent/NO20042925L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20042925A 2001-12-12 2004-07-09 Saltformer av E-2-metoksy-N-(3-(4-(3-metyl-pyridin-3-yloksy)-fenylamino)-kinazolin-6-yl)-allyl)acetamid, samt fremstilling og anvendelse derav mot cancer NO20042925L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34088501P 2001-12-12 2001-12-12
PCT/IB2002/004708 WO2003050108A1 (en) 2001-12-12 2002-11-11 Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer

Publications (1)

Publication Number Publication Date
NO20042925L true NO20042925L (no) 2004-09-07

Family

ID=23335337

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042925A NO20042925L (no) 2001-12-12 2004-07-09 Saltformer av E-2-metoksy-N-(3-(4-(3-metyl-pyridin-3-yloksy)-fenylamino)-kinazolin-6-yl)-allyl)acetamid, samt fremstilling og anvendelse derav mot cancer

Country Status (34)

Country Link
US (1) US6844349B2 (no)
EP (1) EP1456199A1 (no)
JP (1) JP4202926B2 (no)
KR (1) KR20040065259A (no)
CN (1) CN1608062A (no)
AP (1) AP2004003059A0 (no)
AR (1) AR037772A1 (no)
AU (1) AU2002366581A1 (no)
BR (1) BR0214876A (no)
CA (1) CA2469889A1 (no)
DO (1) DOP2002000544A (no)
EA (1) EA007412B1 (no)
EC (1) ECSP045148A (no)
GE (1) GEP20063872B (no)
GT (1) GT200200272A (no)
HR (1) HRP20040530A2 (no)
HU (1) HUP0402662A2 (no)
IL (1) IL161915A0 (no)
IS (1) IS7227A (no)
MA (1) MA27095A1 (no)
MX (1) MXPA04005678A (no)
NO (1) NO20042925L (no)
NZ (1) NZ532436A (no)
OA (1) OA12735A (no)
PA (1) PA8561401A1 (no)
PE (1) PE20030716A1 (no)
PL (1) PL370858A1 (no)
RS (1) RS46404A (no)
TN (1) TNSN04112A1 (no)
TW (1) TW200301103A (no)
UA (1) UA75482C2 (no)
UY (1) UY27572A1 (no)
WO (1) WO2003050108A1 (no)
ZA (1) ZA200402995B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0501069A2 (en) * 2001-12-12 2006-06-28 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
ES2400339T3 (es) 2002-07-15 2013-04-09 Symphony Evolution, Inc. Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
BR0317433A (pt) * 2002-12-18 2005-11-16 Pfizer Prod Inc Derivados bicìclicos para o tratamento do crescimento celular anormal
JP2006512355A (ja) * 2002-12-19 2006-04-13 ファイザー・プロダクツ・インク E−2−メトキシ−n−(3−{4−[3−メチル−4−(6−メチルピリジン−3−イルオキシ)−フェニルアミノ]−キナゾリン−6−イル}−アリル)−アセトアミドの複合体、それらの製造方法および使用
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
BRPI0413745A (pt) * 2003-08-18 2006-10-24 Pfizer Prod Inc horário mde dosagem para agentes anticancerìgenos erbb2
EP2612853A1 (en) 2003-09-26 2013-07-10 Exelixis Inc. c-Met modulators and methods of use
EP1682135B1 (en) * 2003-10-27 2011-07-27 Merck Sharp & Dohme Corp. salt of a tetrahydropyranyl cyclopentyl tetrahydropyridopyridine derivative as CCR2-antagonist
US20050192298A1 (en) * 2004-02-27 2005-09-01 Pfizer Inc Crystal forms of E-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide
WO2005121124A1 (en) * 2004-06-07 2005-12-22 Pfizer Products Inc. Complexes of e-2-methoxy-n-(3-{4-[3-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and methods of preparing same
UA88313C2 (ru) 2004-07-27 2009-10-12 Гилиад Сайенсиз, Инк. Фосфонатные аналоги соединений ингибиторов вич
EP1896451A2 (en) * 2005-06-03 2008-03-12 Pfizer Products Incorporated Bicyclic derivatives for the treatment of abnormal cell growth
CA2610661A1 (en) * 2005-06-03 2006-12-07 Pfizer Products Inc. Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
PT2020996E (pt) * 2006-05-16 2012-02-20 Gilead Sciences Inc Método e composições para tratar neoplasias malignas hematológicas
JPWO2008072634A1 (ja) 2006-12-12 2010-04-02 武田薬品工業株式会社 縮合複素環化合物
CN101611029B (zh) * 2006-12-21 2014-09-10 辉瑞产品公司 2-((4-(1-甲基-4-(吡啶-4-基)-1h-吡唑-3-基)苯氧基)甲基)喹啉的琥珀酸盐
AU2008236995A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Dosages and methods for the treatment of cancer
TW200944528A (en) 2008-03-12 2009-11-01 Takeda Pharmaceutical Fused heterocyclic compound
EA018308B1 (ru) 2008-07-08 2013-07-30 Джилид Сайэнс, Инк. Соли соединений ингибиторов вич
TWI447108B (zh) 2009-01-16 2014-08-01 Exelixis Inc N-(4-{〔6,7雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽及其結晶型
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
WO2017003668A1 (en) 2015-07-01 2017-01-05 California Institute Of Technology Cationic mucic acid polymer-based delivery systems
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
PL3661937T3 (pl) 2017-08-01 2021-12-20 Gilead Sciences, Inc. Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6884418B1 (en) * 1989-08-04 2005-04-26 Berlex Laboratories, Inc. Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DK0912559T3 (da) * 1996-07-13 2003-03-10 Glaxo Group Ltd Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
EE200200710A (et) * 2000-06-22 2004-06-15 Pfizer Products Inc. Asendatud bitsüklilised derivaadid ebanormaalse rakukasvu raviks

Also Published As

Publication number Publication date
GEP20063872B (en) 2006-07-10
EA007412B1 (ru) 2006-10-27
AP2004003059A0 (en) 2004-06-30
HRP20040530A2 (en) 2004-10-31
IL161915A0 (en) 2005-11-20
GT200200272A (es) 2003-12-12
HUP0402662A2 (hu) 2005-05-30
WO2003050108A8 (en) 2003-12-18
MXPA04005678A (es) 2004-12-06
BR0214876A (pt) 2004-12-28
RS46404A (en) 2006-10-27
NZ532436A (en) 2006-01-27
UY27572A1 (es) 2003-07-31
US6844349B2 (en) 2005-01-18
PL370858A1 (en) 2005-05-30
CA2469889A1 (en) 2003-06-19
AR037772A1 (es) 2004-12-01
JP2005511744A (ja) 2005-04-28
KR20040065259A (ko) 2004-07-21
DOP2002000544A (es) 2003-06-16
ZA200402995B (en) 2005-04-20
EA200400674A1 (ru) 2004-10-28
PE20030716A1 (es) 2003-08-29
ECSP045148A (es) 2004-07-23
US20030158217A1 (en) 2003-08-21
MA27095A1 (fr) 2004-12-20
UA75482C2 (en) 2006-04-17
TNSN04112A1 (fr) 2006-06-01
WO2003050108A1 (en) 2003-06-19
AU2002366581A1 (en) 2003-06-23
CN1608062A (zh) 2005-04-20
JP4202926B2 (ja) 2008-12-24
PA8561401A1 (es) 2005-02-04
TW200301103A (en) 2003-07-01
EP1456199A1 (en) 2004-09-15
OA12735A (en) 2006-06-29
IS7227A (is) 2004-04-19

Similar Documents

Publication Publication Date Title
NO20042925L (no) Saltformer av E-2-metoksy-N-(3-(4-(3-metyl-pyridin-3-yloksy)-fenylamino)-kinazolin-6-yl)-allyl)acetamid, samt fremstilling og anvendelse derav mot cancer
DK1474420T3 (da) Quinazolinforbindelser
DK2206702T3 (da) Bicyklisk forbindelse, fremstilling og anvendelse deraf
DE60236367D1 (de) Echolöscher, der eine weitere reduktion des restechos sicherstellt
NO20034159L (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
NO20035121D0 (no) Ny anvendelse
NO20035573L (no) Kinazolinderivater
DE50208733D1 (de) Sicherheitsklebeband
PT1387923E (pt) Coroa de perfuracao.
DE50205704D1 (de) Verbundanker
ATA19802001A (de) Abseilvorrichtung
NO20042613L (no) Ny anvendelse for behandling av gastroosofagial refluks
ATE459085T1 (de) Temperaturbegrenzer
ES1050610Y (es) Tornillo de seguridad.
ATE299873T1 (de) Substituierte c-furan-2-yl-methylamin- und c- thiophen-2-yl-methylamin-derivate
NO20033919L (no) Ny anvendelse
NL1023684A1 (nl) Tweebladig metselwerk en verbindingselement daarvoor.
FI5259U1 (fi) Kehto
NO20041953D0 (no) Handgranat
DE50209548D1 (de) Substituierte 1-aryl-but-3-enylamin- und 1-aryl-but-2-enylaminverbindungen
FI20011722A0 (fi) Menetelmä tärkkelyksen modifioimiseksi, tärkkelys ja sen käyttö
DE60222567D1 (de) Glutaminase
FR2827905B1 (fr) Echelles securisees
ITTO20020476A1 (it) Composti pironici e loro utilizzo.
ATA14772001A (de) Handgranate

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application